[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 24, 1997

Brain Serotonin Neurotoxicity and Fenfluramine and Dexfenfluramine

Author Affiliations

Fairfax,Va

JAMA. 1997;278(24):2142. doi:10.1001/jama.1997.03550240032023
Abstract

To the Editor.  —Dr McCannnd colleagues1 state "subsequently, several centers reported cases of PPH [primary pulmonary hypertension] in users of anorexigens, both amphet-aminelike drugs and serotonin uptake inhibitor agents." A similar statement implicating "amphetamine-type" agents in PPH also appeared in an earlier review by one of the authors.2 Unless rigorous data support such statements, it is incorrect to link entire classes of medication, whether grouped according to their approved indication or according to their mechanism of action, to a particular adverse effect. For example, there is no evidence linking selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine or sertraline to PPH. Indeed, the authors are probably referring to fenfluramine, which, unlike the SSRIs, is a substrate of the 5-hydroxytryptamine (5-HT) transporter and therefore releases 5-HT. Similarly, the term amphetaminelike is ill defined. Does this refer to the chemical structure, to a stimulant effect in animal behavioral assays, or to an

×